Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"

NCT02824133 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion
Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion

Interventions

DRUG: AZD4547

Sponsor

Assistance Publique - Hôpitaux de Paris